Abstract | BACKGROUND: METHODS: RESULTS:
Tranexamic acid and epsilon-aminocaproic acid produced a significant reduction in postoperative blood loss compared with placebo (median loss, 438 mL, 538 mL, and 700 mL, respectively). Transfusion of red cells was similar in all three groups. Nonetheless, the percentage of patients receiving hemostatic blood products was significantly decreased in the epsilon-aminocaproic acid group compared with the placebo group (20% versus 43%; p = 0.03). Both tranexamic acid and epsilon-aminocaproic acid significantly decreased total exposure to allogeneic blood products compared with placebo (p = 0.01 and p = 0.05, respectively), and this reduction was clinically important (median exposure, 2, 2, and 7.5 units, respectively). Fibrinolysis was inhibited significantly in both treatment groups. CONCLUSIONS:
|
Authors | J F Hardy, S Bélisle, C Dupont, F Harel, D Robitaille, M Roy, L Gagnon |
Journal | The Annals of thoracic surgery
(Ann Thorac Surg)
Vol. 65
Issue 2
Pg. 371-6
(Feb 1998)
ISSN: 0003-4975 [Print] Netherlands |
PMID | 9485231
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antifibrinolytic Agents
- Tranexamic Acid
- Aminocaproic Acid
|
Topics |
- Aminocaproic Acid
(administration & dosage)
- Antifibrinolytic Agents
(administration & dosage)
- Blood Loss, Surgical
(prevention & control)
- Blood Transfusion
- Coronary Artery Bypass
- Double-Blind Method
- Female
- Humans
- Male
- Postoperative Complications
- Premedication
- Prospective Studies
- Reoperation
- Tranexamic Acid
(administration & dosage)
|